SCHEMBL6184899

SCHEMBL6184899

O=C1NC(=O)C(=Cc2ccc(-c3cccc(C(=O)O)c3)cc2)S1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 2/20 0.67
TDP1 Q9NUW8 2/20 0.60
MEN1 O00255 1/20 0.58
POLB P06746 1/20 0.58
KMT2A Q03164 1/20 0.58
PIM1 P11309 4/20 0.57
PIM2 Q9P1W9 4/20 0.57
PIM3 Q86V86 1/20 0.57
HPGD P15428 4/20 0.56
AKR1B1 P15121 3/20 0.56
NAT1 P18440 1/20 0.56
MYC P01106 1/20 0.54
IL1RN P18510 1/20 0.54
ERAP1 Q9NZ08 1/20 0.54
TDP2 O95551 1/20 0.53
GSK3B P49841 2/20 0.53
GSK3A P49840 1/20 0.53
RAB9A P51151 1/20 0.52
CISD1 Q9NZ45 2/20 0.52
MAOA P21397 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6184897 1.00 PIK3CG (0.67) PIK3CGTDP1MEN1POLBKMT2A
SCHEMBL6183587 0.88 MEN1 (0.60) PIK3CGTDP1MEN1POLBKMT2A
SCHEMBL6183585 0.88 MEN1 (0.60) PIK3CGTDP1MEN1POLBKMT2A
SCHEMBL12892083 0.88 TDP1 (0.76) PIK3CGTDP1PIM1PIM2PIM3
SCHEMBL1250449 0.88 TDP1 (0.76) PIK3CGTDP1PIM1PIM2PIM3
SCHEMBL1250447 0.88 TDP1 (0.76) PIK3CGTDP1PIM1PIM2PIM3
SCHEMBL5145910 0.85 PIK3CG (0.62) PIK3CGTDP1MEN1POLBKMT2A
SCHEMBL5145908 0.85 PIK3CG (0.62) PIK3CGTDP1MEN1POLBKMT2A
SCHEMBL12891790 0.83 PIM1 (0.83) PIK3CGTDP1MEN1POLBKMT2A
SCHEMBL1248780 0.83 PIM1 (0.83) PIK3CGTDP1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
EP-1309575-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS Galderma Research & Development (FR) 2003-05-14 EP disclosed
WO-2002012210-A9 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2002-04-18 WO disclosed
WO-2002012210-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD PIK3CG 1138/4885TDP1 2672/4885MEN1 4750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.